PPM Oost invests in Syntarga

The company develops highly potent cell-killing drugs, releasable linker technologies and linker-drug combinations for conjugation to tumor-specific antibodies. Based in Nijmegen, the company was founded in 2002 and closed a series-A funding round in 2005.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Viktor Lundvall on +44 20 7004 7476 or viktor.lundvall@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare
• Early-stage
• Netherlands